Table 4.

Ongoing clinical trials on immune checkpoint inhibitors and locoregional therapies for patients with advanced HCC

Drug and treatment	Phase	Setting	Primary endpoint	ClinicalTrials.gov identifier
Lenvatinib and pembrolizumab and TACE vs. TACE	III	First-line	PFS, OS	NCT04246177 (LEAP-012)*
Tremelimumab and durvalumab and radiation therapy	II	First-line	ORR	NCT03482102
Pembrolizumab and SBRT	II	Second-line	ORR	NCT03316872
Durvalumab and tremelimumab and ablative therapies	II	Second-line	PFS	NCT02821754
Pembrolizumab and SIRT	I	First-line	PFS	NCT03099564
SBRT followed by sintilimab vs. SBRT	II/III	First-line	PFS	NCT04167293
HAIC and apatinib and camrelizumab	II	First-line	ORR	NCT04191889
Toripalimab and thermal ablation	II	Second-line	PFS	NCT03864211
TACE and sintilimab	II	First-line	ORR	NCT04297280

HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PFS, progression-free survival; OS, overall survival; ORR, objective response rate; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiation therapy; HAIC, hepatic arterial infusion chemotherapy.

^*Study name.